StockData
Fate Therapeutics Inc logo

Fate Therapeutics Inc (FATE) stock

FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3024% below fair value
$1.02−0.12 (-10.53%)

Close on Nov 17, 2026Market cap $122.22MP/E –Yield –

Fate Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Fate Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$101.91M. For fiscal 2025 it was -$106.08M. The highest annual figure on record is -$12.15M in fiscal 2011.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$106.08M–
FY2024Dec 31, 2024-$122.87M–
FY2023Dec 31, 2023-$132.26M–
FY2022Dec 31, 2022-$248.21M–
FY2021Dec 31, 2021-$162.87M–
FY2020Dec 31, 2020-$39.23M–
FY2019Dec 31, 2019-$83.18M–
FY2018Dec 31, 2018-$38.65M–
FY2017Dec 31, 2017-$36.82M–
FY2016Dec 31, 2016-$29.82M–
FY2015Dec 31, 2015-$18.40M–
FY2014Dec 31, 2014-$22.42M–
FY2013Dec 31, 2013-$15.37M–
FY2012Dec 31, 2012-$13.27M–
FY2011Dec 31, 2011-$12.15M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$23.40M–
Q1 FY2026Mar 31, 2026-$30.82M–
Q4 FY2025Dec 31, 2025-$23.31M–
Q3 FY2025Sep 30, 2025-$24.37M–
Q2 FY2025Jun 30, 2025-$24.59M–
Q1 FY2025Mar 31, 2025-$33.81M–
Q4 FY2024Dec 31, 2024-$27.80M–
Q3 FY2024Sep 30, 2024-$29.42M–
Q2 FY2024Jun 30, 2024-$32.31M–
Q1 FY2024Mar 31, 2024-$33.35M–
Q4 FY2023Dec 31, 2023-$36.64M–
Q3 FY2023Sep 30, 2023-$38.27M–
Q2 FY2023Jun 30, 2023-$28.49M–
Q1 FY2023Mar 31, 2023-$28.86M–
Q4 FY2022Dec 31, 2022-$75.39M–
Q3 FY2022Sep 30, 2022-$55.05M–
Q2 FY2022Jun 30, 2022-$53.16M–
Q1 FY2022Mar 31, 2022-$64.61M–
Q4 FY2021Dec 31, 2021-$70.29M–
Q3 FY2021Sep 30, 2021-$33.38M–
Q2 FY2021Jun 30, 2021-$32.11M-182.7%
Q1 FY2021Mar 31, 2021-$27.10M–
Q4 FY2020Dec 31, 2020-$20.66M–
Q3 FY2020Sep 30, 2020-$30.73M–
Q2 FY2020Jun 30, 2020$38.84M–
Q1 FY2020Mar 31, 2020-$26.67M–
Q4 FY2019Dec 31, 2019-$25.54M–
Q3 FY2019Sep 30, 2019-$19.84M–
Q2 FY2019Jun 30, 2019-$20.31M–
Q1 FY2019Mar 31, 2019-$17.49M–
Q4 FY2018Dec 31, 2018-$11.02M–
Q3 FY2018Sep 30, 2018-$3.56M–
Q2 FY2018Jun 30, 2018-$11.52M–
Q1 FY2018Mar 31, 2018-$12.55M–
Q4 FY2017Dec 31, 2017-$10.72M–
Q3 FY2017Sep 30, 2017-$9.77M–
Q2 FY2017Jun 30, 2017-$8.87M–
Q1 FY2017Mar 31, 2017-$7.46M–
Q4 FY2016Dec 31, 2016-$7.55M–
Q3 FY2016Sep 30, 2016-$7.52M–

More Fate Therapeutics figures

See a number that looks wrong?